je.st
news
Tag: response
Investigational Brain Cancer Vaccine Produces Strong Immunological Response
2015-04-22 05:44:58| drugdiscoveryonline Home Page
A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in patients with recurrent or progressive malignant brain tumors, according to results of a phase I study conducted by Roswell Park Cancer Institute (RPCI) researchers.
Tags: strong
response
cancer
brain
Whitehorse says illegal dumping response costs $50K per year
2015-04-21 21:26:06| Solid Waste & Recycling magazine Headlines
Citys waste department says the latest fuel spill cost upwards of $2,000 to clean The post Whitehorse says illegal dumping response costs $50K per year appeared first on Solid Waste & Recycling Magazine.
Tags: year
costs
response
illegal
Type K Thermocouple Amplifier offers dynamic response of 1 mS.
2015-04-20 14:31:08| Industrial Newsroom - All News for Today
With temperature measuring range of 0–1,250°C, Model TCA-MS-K-1 converts low output voltage signal from Type K thermocouple probe to single independent linearized 0–5 Vdc output voltage. Single-channel unit interfaces to instrumentation equipment including data loggers, temperature indicators, chart recorders, and controllers. Supplied in IP51-rated housing measuring 2.5 x 2.5 x 0.9 in., amplifier includes mini-plug signal input connector and 1 m long integral signal cable.
KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
2015-04-19 14:30:00| Merck.com - Product News
Dateline City: PHILADELPHIA ...in a Phase 3 Study of Patients with Advanced Melanoma Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine Merck Plans to Submit sBLA for First-Line Indication in Advanced Melanoma in Mid-2015 PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, 2015, Merck announced that KEYNOTE-006 would be stopped early based on these data (link). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: free
rate
response
compared
Recycling, Composting System In San Francisco Park Unveiled In Response To Abundance Of Trash Left By Picnickers
2015-04-17 00:48:00| Waste Age
<a href="http://sanfrancisco.cbslocal.com/">CBS San Francisco</a> A pop-up recycling and composting system was unveiled Wednesday in response to an abundance of litter left behind by picnickers at San Franciscos Dolores Park. read more
Sites : [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] next »